XORTX Therapeutics logo

XORTX TherapeuticsNASDAQ: XRTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Canada

IPO:

23 September 2021

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$4.52 M
-98%vs. 3y high
12%vs. sector
-vs. 3y high
-vs. sector
-92%vs. 3y high
51%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Mon, 28 Oct 2024 20:00:00 GMT
$1.56+$0.05(+2.99%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

XRTX Latest News

XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement
globenewswire.com18 October 2024 Sentiment: POSITIVE

CALGARY, Alberta, Oct. 18, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, today announced that it has closed its registered direct offering and concurrent private placement, announced on October 17, 2024, for the purchase and sale of 810,810 common shares (or pre-funded warrants in lieu thereof) in a registered direct offering and common warrants to purchase up to 810,810 common shares in a concurrent private placement (together with the registered direct offering, the “Offering”) at a combined purchase price of US$1.85 per common share. The common warrants issued pursuant to the concurrent private placement have an exercise price of US$2.18, are immediately exercisable and expire five years from issuance.

XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A
globenewswire.com12 September 2024 Sentiment: POSITIVE

CALGARY, Alberta, Sept. 12, 2024 (GLOBE NEWSWIRE) --  XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has refiled its management's discussion and analysis (“MD&A”) for the financial year ended December 31, 2023 and for the interim period ended June 30, 2024 as a result of a continuous disclosure review by the Alberta Securities Commission.

XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders
globenewswire.com06 September 2024 Sentiment: POSITIVE

CALGARY, Alberta, Sept. 06, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, reminds shareholders of the upcoming deadline to vote at the Company's Annual General and Special Meeting (the "Meeting"), which is scheduled to be held on September 12, 2024.

Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders
globenewswire.com03 September 2024 Sentiment: POSITIVE

CALGARY, Alberta, Sept. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has recommended Shareholders vote “FOR” all the proposed resolutions at the upcoming Annual and Special Meeting of Shareholders (the “Meeting”) to be held on September 12, 2024.

XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
globenewswire.com23 August 2024 Sentiment: POSITIVE

CALGARY, Alberta, Aug. 23, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the management information circular (the “Circular”) for the annual and special meeting (the “Meeting”) of shareholders is now available on the Company's website at https://www.xortx.com/investors/news-events/ir-calendar/detail/7671/annual-and-special-meeting-of-shareholders as well as on the Company's SEDAR+ profile (www.sedarplus.ca) and the SEC's website (www.sec.gov). The mailing of the Circular and related Meeting materials occurred on August 21, 2024.

XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024
globenewswire.com20 August 2024 Sentiment: POSITIVE

Health consequences of over active xanthine oxidase may accelerated PKD progression Health consequences of over active xanthine oxidase may accelerated PKD progression

XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO
globenewswire.com17 May 2024 Sentiment: POSITIVE

CALGARY, Alberta, May 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company specializing in treatments for progressive kidney disease, has received approval from the TSX Venture Exchange to adjust the terms of outstanding common share purchase warrants issued on October 15, 2021. The original exercise price of the warrants, which were previously repriced in connection with a private placement on October 7, 2022, has been amended to USD $5.00 on a post-consolidation basis for 910,000 warrants (101,111 post 9:1 consolidation).

Why Is Xortx Therapeutics (XRTX) Stock Down 27% Today?
InvestorPlace23 October 2023 Sentiment: NEGATIVE

Xortx Therapeutics (NASDAQ: XRTX ) stock is sliding lower on Monday as the pharmaceutical company's shares come off of a recent rally. Shares of XRTX stock closed out normal trading hours on Friday up 100.6%.

Why Is Xortx Therapeutics (XRTX) Stock Up 110% Today?
InvestorPlace20 October 2023 Sentiment: POSITIVE

Xortx Therapeutics (NASDAQ: XRTX ) stock is climbing higher on Friday despite a lack of news from the pharmaceutical company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) from Xortx Therapeutics that would cause today's rally.

What type of business is XORTX Therapeutics?

XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.

What sector is XORTX Therapeutics in?

XORTX Therapeutics is in the Healthcare sector

What industry is XORTX Therapeutics in?

XORTX Therapeutics is in the Biotechnology industry

What country is XORTX Therapeutics from?

XORTX Therapeutics is headquartered in Canada

When did XORTX Therapeutics go public?

XORTX Therapeutics initial public offering (IPO) was on 23 September 2021

What is XORTX Therapeutics website?

https://www.xortx.com

Is XORTX Therapeutics in the S&P 500?

No, XORTX Therapeutics is not included in the S&P 500 index

Is XORTX Therapeutics in the NASDAQ 100?

No, XORTX Therapeutics is not included in the NASDAQ 100 index

Is XORTX Therapeutics in the Dow Jones?

No, XORTX Therapeutics is not included in the Dow Jones index

When was XORTX Therapeutics the previous earnings report?

No data

When does XORTX Therapeutics earnings report?

Next earnings report date is not announced yet